A recent view market research of U.S. adults beside roomy cholesterol establish that contained via nastiness of concern more or less the key finality stake associated with their condition, such by heart robbery, cuddle and coronary heart illness, in that be a vital disconnect concerning intellectual size what should be done to computer screen and dominate high cholesterol and if legitimacy be tell implement recommended change to demean cholesterol rank.
Sponsored by Daiichi Sankyo and conduct by Harris Interactive, the survey of 400 adults diagnose with high cholesterol found that nearly one and all (95 percent) agreed that a tweaking in diet and even training would be their in route to lower cholesterol. Yet, separate partly (50 percent) read aloud they be doing everything they can to lower their cholesterol. Many are nervous about the opportunity that prescription medication will ruin their liver (83 percent) and kidneys (80 percent), but only three-fourths (73 percent) envelop discuss risks and players effects with their doctors.
Survey respondents habitually turn aware to have other cardiovascular risk factor, plus hypertension (52 percent), diabetes (29 percent) and coronary heart disease (14 percent).
Cardiovascular disease dregs the figure one impose of demise and disability in the U.S., claim higher than 870,000 live all year.(1) Currently, more than 100 million American adults, about one third of the U.S. population, have a full blood cholesterol level highly developed than 200 mg/dL, which put them at risk all for cardiovascular disease.(2) The survey also indicate that while furthermost (91 percent) say it is important to them to have cholesterol checked habitually, nearly half (46 percent) of those with high cholesterol are not firm what their total cholesterol level is, and four in five respondents (80 percent) aren’t sure what their LDL (”bad” cholesterol) level is. This unawareness may also affect cholesterol dream. Half don’t have a total cholesterol goal and 79 percent don’t have an LDL level goal. Further, about half of adults with high cholesterol (52 percent) apply not guess their LDL cholesterol level is a serious risk to their health.
The 2007 high cholesterol survey, sponsor by Daiichi Sankyo, Inc., is a tail skilled of resembling survey conducted in 2000 and 2004.
“This survey epitomize that although all the news at your disposal today about high cholesterol, and the enormity of health snags associated with elevated levels, copious tribal group don’t come across to be making all the lifestyle changes elemental to address the mess. There is a significant distance between understanding the health risks associated with high cholesterol and knowing what their personal total and LDL cholesterol levels are, and the goals of health-giving,” said Peter H. Jones, MD, Baylor College of Medicine. “The survey also shows a necessitate for physician to express sympathy about treatment remedy and safekeeping, including non-systemic or non-absorbed medications,” added Dr. Jones.
Survey respondents said that important characteristics of a cholesterol- lower medication are: that the medication is easy to stand for (91 percent); that the medication can be nearly new undamagingly in pairing with other drugs (89 percent); that the medication do not pulse through their liver or kidneys (84 percent); and that the linctus does not need blood carry out to monitor side effects of the liver (83 percent).
The prevailing globular table of non-systemic cholesterol-lowering medications is the bile tart sequestrant class (BAS). The pigeonholed boss of that class, WelChol(R), is an influential option with a ingrained safety profile for patients with high LDL cholesterol.(3) WelChol differ from many other LDL cholesterol-lowering medications adjacent to the marketplace because it is non-absorbed, worth that the element does not occupy it and it is get rid of minus affecting the liver, kidney or other target organs.
“WelChol may be a viable option for those who certificate the benefits of taking LDL cholesterol-lowering medications but are concerned about undeveloped adverse side effects noted with other prescription options,” tag on Dr. Jones.
For the meaning of this survey, those with “high cholesterol” be defined as U.S. adults (ages 20) who have be diagnosed with high cholesterol and are doing something to be in bid of their condition, including exercise regularly, shifting diet, taking prescription medication, taking over-the-counter medication or ingestion cholesterol lowering stores products.
About WelChol(R) WelChol is indicate for LDL-C lowering and be voted for by the U.S. Food and Drug Administration (FDA) for marketing in May 2000. WelChol is the top- selling branded drug in the bile acid sequestrants (BAS) class. WelChol is differing from most other cholesterol-lowering drugs on the market because it is non-systemic, meaning that the body does not absorb it and it is eliminated without traveling to the liver or kidneys. Therefore, WelChol is not anticipated to have drug-drug interactions via the cytochrome P-450 pathway. Systemic medications, which catch statins, fibrates, and cholesterol digestion inhibitors, are those that are immersed from the intestine into the bloodstream and shift in the body, clearly to the liver and/or kidneys.
WelChol is a prescription drug indicated alone or in combination with a statin, as an adjunct to diet and exercise for the contraction of elevated LDL cholesterol in patients with foremost hypercholesterolemia (Fredrickson Type IIa) when the riposte to diet and exercise have been scarce. Liver- control monitor is not hunted with WelChol when used as monotherapy, and in combination with a statin, no extra liver-function monitoring is required farther than that for the prescribed statin alone.
In clinical trial with patients with primary hypercholesterolemia, when WelChol was given alone and to a diet diet and exercise, it was shown to reduction LDL cholesterol by an middling of 15% to 18%.
When WelChol is given in combination with a statin, the combination can lower cholesterol levels more effectively than using any treatment alone. In pivotal study where on earth WelChol was taken with a statin, WelChol 3.8 g present up to an additional plan 16% (32 mg/dL) reduction in LDL cholesterol. WelChol is the only non-systemic cholesterol-lowering agent approved by the FDA for combination with a statin. WelChol can be used in combination with any dose of any statin.
WelChol is engineered for affinity and high capacity bile acid unchangeable. It has been studied with four universally prescribed statins - Lipitor(R) (atorvastatin calcium), Zocor(R) (simvastatin), Pravachol(R) (pravastatin sodium) and Mevacor(R) (lovastatin). Additionally, WelChol has been studied with fenofibrate and have no significant effect on the bioavailability of fenofibrate. Like most prescription drugs, WelChol has not been studied in combination with all medications or extra. Patients should always allotment their surgeon about all medications and supplements they are taking in the ex- starting any fresh therapy, including WelChol.
WelChol is not for everyone, even more those with bowel bottleneck. Caution should be exercise when treat patients who have problem sip or tough tummy or intestinal problems.
Chlamydia be the furthermost ubiquitous sexually blind bug, delimited via Washington State, USA it grow 12% in a year, making it a account year. Health official in Washington be urging all sexually influential women humiliate than the age of 25 to personal an annual tryout.
WelChol is only indicated for the reduction of LDL-C either alone or in combination with a statin in patients with primary hypercholesterolemia. Additionally, WelChol has demonstrated valuable effects on other lipid parameter such as HDL-C and APO-B. WelChol has also been studied in combination with fenofibrate in patients with sundry dyslipidemia (Fredrickson Type II B), and provided additional LDL-C reduction in these patients when added to a floating fenofibrate regimen. WelChol is not indicated for multiplicity the most of in the treatment of mixed dyslipidemia or lipid parameters excluding LDL-C.
About Daiichi Sankyo, Inc.
Daiichi Sankyo, Inc., headquartered in Parsippany, New Jersey, is the U.S. subsidiary of Daiichi Sankyo Co., Ltd., Japan’s second largest pharmaceutical form and a intercontinental leader in pharmaceutical newness since 1899. The company is dyed-in-the-wool to the honour, movement and commercialization of anarchistic drug that rearrange the lives of patients throughout the world.
The primary focus of Daiichi Sankyo’s research and development is cardiovascular disease, including therapy for dyslipidemia, hypertension, diabetes, and acute coronary syndrome. The company is also research the discovery of new medicines in the area of glucose metabolic disorders, easily propagate disease, cancer, prepare and collective diseases, and immune disorders.
Psoriatic Arthritis: HUMIRA is indicated for the treatment of active and progressive psoriatic arthritis in adults when the response to aforementioned disease-modifying antirheumatic tablets therapy has been inadequate.
About the Survey This survey was conducted by easy-to-read inside the United States by Harris Interactive on behalf of Daiichi Sankyo between January 17 and February 5, 2007 among a internally symbolic taster of 400 U.S. adults ages 20 and elder who have been diagnosed with high cholesterol and are doing something to manage it. Management include: exercising regularly, changing diet, taking prescription medication, taking over-the-counter medication or eating cholesterol lowering food products. Figures for age, femininity, race/ethnicity, childhood, subdivision, and household yield were weighted where necessary to convey them into wallow with their actual proportions in the population. With unsullied likelihood sample, with 100 percent response rates, it is would-be to total the probability that the sampling scratch stain (but not other source of error) is not greater than one cipher. With a pure probability sample of 400, one could say with a ninety-five percent probability that the overall grades would have a sampling error of /-6 percentage prickle. Sampling error for information base on subsamples would be higher and would change.
However that does not pilfer other sources of error into account.
About Harris Interactive Harris Interactive is the 12th largest and fastest-growing market research dogged in the world. The company provide innovative research, insight and strategic proposal to give support to its clients make more hopeful finding which front to measurable and everlasting improvements in operation. Harris Interactive is widely specified for The Harris Poll, one of the longest running, self-sufficient opinion poll and for pioneering online market research skill. The company has build what it believe to be the world’s largest panel of survey respondents, the Harris Poll Online. Harris Interactive serve clients experienced through its United States, Europe and Asia department, its wholly-owned subsidiary Novatris in France and MediaTransfer AG in Germany, and through a global grating of independent market research firm. More information about Harris Interactive may be procure at To become a participant of the Harris Poll Online and be invite to assist in online surveys, check at References (1) Circulation. 2007 Heart Disease and Stroke Statistical Update. Dallas, Tex: American Heart Association, 2007. Page e164.
(2) American Heart Association. 2007 High Blood Cholesterol and Other Lipids Statistical Update. Dallas, Tex: American Heart Association, 2007. Page 2.
(3) IMS National Prescription Data, June 22, 2007.
Daiichi Sankyo, Inc.